Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-13	2.440 $	+12.96%	67,970
26-01-12	2.160 $	-8.09%	53,538
26-01-09	2.350 $	-3.29%	41,832
26-01-08	2.430 $	-4.71%	36,349
26-01-07	2.550 $	-5.20%	48,812

Delayed Quote Nasdaq, January 13, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-13 pm EST			5-day change	1st Jan Change
2.440 ^USD	+12.96%		-2.01%	+34.81%

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE

Capitalization	4.35M 3.74M 3.48M 3.24M 6.04M 393M 6.51M 40.06M 15.74M 188M 16.31M 15.97M 692M	P/E ratio 2023 *	-	P/E ratio 2024	-0.82x
Enterprise value	-2.46M -2.12M -1.97M -1.83M -3.42M -222M -3.69M -22.68M -8.91M -106M -9.23M -9.04M -392M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	92.54%	Yield 2023 *	-	Yield 2024	-

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE
Dec. 16	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100	CI
Dec. 12	Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement	MT
Dec. 03	Clearmind Medicine Inc files for offering of up to 16 million common shares - SEC filing	RE
Dec. 02	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
Dec. 02	Clearmind Medicine advances CMND-100 to dosing phase at Hadassah Medical Center	RE
Dec. 01	Clearmind advances alcoholism treatment with positive data, DSMB approval, and new trial site	RE
Dec. 01	Clearmind Medicine Inc. Announces Three Transformative Milestones in its FDA- Approved Phase I/IIa Clinical Trial for CMND-100	CI
Nov. 25	Clearmind Medicine Kicks-Off Patient Enrollment At Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/IIa Alcohol Use Disorder Trial	CI
Nov. 24	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/Iia Clinical Trial for Cmnd-100 Following Positive Interim Safety Review	CI
Nov. 20	Neurothera Labs Inc. Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	CI
Nov. 20	Clearmind Medicine Accelerate Fda-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site	CI

Dec. 31	Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
Dec. 24	Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth	AQ
Dec. 16	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100	AQ
Dec. 12	Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment	AQ
Dec. 12	Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	AQ

Clearmind Medicine Inc. Stock

Equities

CMND

CA1850535016

Biotechnology & Medical Research

Valuation: Clearmind Medicine Inc.

Chart: Clearmind Medicine Inc.

Latest news: Clearmind Medicine Inc.

Analysts' recommendations: Clearmind Medicine Inc.

Press Releases: Clearmind Medicine Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Clearmind Medicine Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+12.96%
1 week	-2.01%
Current month	+34.81%
1 month	-17.90%
3 months	-93.45%
6 months	-93.58%
Current year	+34.81%

1 week	2.07	2.69
1 month	1.74	3.25
Current year	1.84	2.74
1 year	1.74	64
3 years	1.74	6,050.17
5 years	1.74	26,280.07
10 years	1.74	26,280.07

Manager	Title	Age	Since
Gadi Levin CEO	Chief Executive Officer	54	2020-04-15
Adi Zuloff-Shani CEO	Chief Executive Officer	55	2021-07-13
Alan Rootenberg DFI	Director of Finance/CFO	73	2022-06-13

Director	Title	Age	Since
Hila Kiron-Revach BRD	Director/Board Member	45	2024-08-31
Amitay Weiss CHM	Chairman	62	2019-08-18
Oz Adler BRD	Director/Board Member	40	2021-09-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CLEARMIND MEDICINE INC.	+12.96%	-2.01%	-96.01%	-99.96%	3.24M
LONZA GROUP AG	-0.92%	+4.67%	+1.19%	+14.95%	49.9B
IQVIA HOLDINGS INC.	+0.29%	+2.98%	+18.84%	+10.05%	41.02B
BEONE MEDICINES AG	+5.11%	+9.60%	+98.66%	+33.37%	36.96B
CELLTRION, INC.	+3.27%	+5.49%	+24.17%	+43.65%	31.91B
REVOLUTION MEDICINES, INC.	+2.37%	+53.13%	+187.10%	+301.30%	22.65B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-26.23%	+20.34%	+25,481.76%	+4,091.68%	21.81B
MEDPACE HOLDINGS, INC.	+1.54%	+3.68%	+73.41%	+169.31%	16.88B
EUROFINS SCIENTIFIC SE	+1.98%	+8.91%	+49.01%	+13.12%	14.8B
ICON PUBLIC LIMITED COMPANY	+1.74%	-7.23%	-16.01%	-17.68%	13.76B
Average	+2.54%	+11.69%	+2,582.21%	+455.98%	24.97B
Weighted average by Cap.	+1.30%	+12.88%	+2,270.99%	+411.17%

	2023	2024
Net sales	-	-
Net income	-8.62M -7.41M -6.91M -6.42M -11.98M -779M -12.91M -79.42M -31.2M -372M -32.33M -31.67M -1.37B	-5.25M -4.52M -4.21M -3.91M -7.3M -475M -7.87M -48.41M -19.02M -227M -19.71M -19.3M -836M
Net Debt	-5.51M -4.74M -4.42M -4.11M -7.66M -498M -8.26M -50.8M -19.96M -238M -20.68M -20.25M -878M	-6.81M -5.85M -5.46M -5.07M -9.46M -615M -10.2M -62.74M -24.65M -294M -25.54M -25.02M -1.08B